For the Quarter Ending September 2025
North America
• In the United States, the Ivermectin Price Index rose quarter-over-quarter in Q3 2025, driven by increased production costs and declining chemical output.
• Ivermectin production costs increased, influenced by a 2.6% year-over-year rise in PPI in August 2025 and elevated energy costs.
• Demand for Ivermectin faced headwinds from a 3.0% year-over-year CPI increase and declining consumer confidence in September 2025.
• Despite weak overall chemical demand, retail sales increased 5.42% year-over-year in September 2025, supporting some end-use markets.
• Chemical industry inventories shrank in Q3 2025 due to accelerating destocking, impacting overall supply dynamics.
• Industrial production grew only 0.1% year-over-year in September 2025, reflecting subdued activity and a decline in chemical output.
• Foreign orders for the chemical industry declined in Q3 2025, alongside a fall in US exports in July 2025.
• The unemployment rate of 4.3% in September 2025 indicated a stable labor market, influencing labor costs for manufacturers.
Why did the price of Ivermectin change in September 2025 in North America?
• Increased input and raw materials costs, alongside elevated energy prices, drove Ivermectin production expenses.
• A 2.6% year-over-year PPI increase in August 2025 signaled rising producer costs, impacting Ivermectin.
• Declining chemical output in September 2025, coupled with shrinking inventories, tightened supply.
APAC
• In China, the Ivermectin Price Index fell quarter-over-quarter in Q3 2025, driven by persistent overcapacity and contracting manufacturing activity.
• Ivermectin production costs declined in Q3 2025, as PPI fell by 2.3% in September 2025 and energy costs eased.
• Demand for Ivermectin was supported by 6.5% industrial production growth in September 2025 and a thriving pharmaceutical industry.
• The veterinary medicine market experienced growth in Q3 2025, bolstering Ivermectin demand despite consumer confidence at 89.6.
• Retail sales rose by 3.0% in September 2025, yet CPI fell by 0.3%, indicating mixed signals for Ivermectin demand.
• Stable unemployment at 5.2% in September 2025 sustained consumer spending on healthcare and pet care products.
• Persistent overcapacity in China's chemical industry exerted downward pressure on Ivermectin prices during Q3 2025.
• Corn starch feedstock costs stabilized in Q3 2025, influenced by improved logistics and easing energy costs.
Why did the price of Ivermectin change in September 2025 in APAC?
• Falling PPI by 2.3% in September 2025 reduced raw material costs for Ivermectin producers.
• Contracting Manufacturing Index in September 2025 signaled weaker industrial demand for chemical inputs.
• Persistent overcapacity in China's chemical industry during Q3 2025 exerted downward pressure on prices.
Europe
• In Germany, the Ivermectin Price Index fell quarter-over-quarter in Q3 2025, influenced by contracting industrial activity.
• Ivermectin production costs faced persistent industry-wide increases in Q3 2025, despite moderating European natural gas prices.
• Ivermectin demand outlook weakened in Q3 2025, as the Manufacturing Index contracted and industrial production declined.
• Inflationary pressures, indicated by a 2.4% year-over-year CPI in September 2025, affected operational expenses.
• Producer input costs showed deflationary trends, with PPI declining by 1.7% year-over-year in September 2025.
• Significantly negative consumer confidence of -23.6 in September 2025 suggested cautious spending, pressuring demand.
• German chemical and pharmaceutical industry production declined in Q3 2025, with capacity utilization below profitability.
• International sales for the German chemical and pharmaceutical industry weakened significantly in Q3 2025.
• A low unemployment rate of 3.9% in September 2025 indirectly supported consumer spending capacity.
Why did the price of Ivermectin change in September 2025 in Europe?
• Contracting industrial activity, with the Manufacturing Index contracting in September 2025, reduced demand.
• Weakening international sales for German chemical products in Q3 2025 increased supply pressure.
• Persistent high industry costs in Q3 2025 maintained upward pressure on production expenses.
For the Quarter Ending December 2022
North America
Ivermectin had shifting market patterns in the North American region during the fourth quarter of 2022. Beginning with Q4 2022, prices were predicted to rise through the second month of this quarter due to a high cost of manufacturing, numerous logistical problems, and growing inflation.
Additionally, the market position was maintained well by rising transportation costs and port congestion at the major ports. Moreover, the market was favorably impacted by disorganization, a slowdown in API production, and rising energy prices. Prices begin to decline later in December 2022 due to softening inflation and declining end-user sector demand. Ivermectin prices were accessed at USD 138580/MT CFR Houston at the end of Q4 with an average quarterly tendency of 0.87%.
Asia
In the fourth quarter of 2022, the Ivermectin market witnessed fluctuating trajectory in the Asia Pacific region. At the commencement of Q4 2022, the prices were recorded to increase until the second month of Q4 due to increasing demand from the end-user sector, several logistic issues, and rising inflation. Also, the strict zero-COVID policies and repeated lockdowns in the Chinese provinces affected the market. The increased production cost on the back of rising energy prices and increased domestic manufacturing to cater to regional and international orders kept the market tight. However, later in December 2022, the prices of Ivermectin went down as the domestic merchants had enough inventories on their shelves. Further, the ease in the policies, along with low downstream demand, kept the market feeble. Towards the end of Q4, the prices of Ivermectin were recorded at USD 127250/MT FOB Shanghai (China), with an average quarterly declination of 0.52%.
Europe
In the Fourth quarter of 2022, the prices of Ivermectin showcased a see-saw trajectory in the European region. The downstream pharmaceutical sector's demand for Ivermectin was recorded to be consistent. However, the ongoing port congestion and supply disruption in the European region affected the supply chain and compelled the prices to increase in the first two months of Q4 022. Also, the high freight charges contributed to the hiked-up trajectory of Ivermectin. The European merchants decide to restock their inventories in bulk on the back of nearing the festive season to cater to the demand. Nevertheless, the prices dropped in December due to existing inventories and lowering demand from the end-user sector. Towards the end of Q4 2022, the prices of Ivermectin were recorded at USD 140200/MT with an average quarterly inclination of 0.35%.
For the Quarter Ending September 2022
North America
The prices of Ivermectin showcased contracting behavior in the North American region. At the onset of Q3 2022, the costs decreased due to ease in the pandemic situation in exporting countries following the resumption of production units. Equilibrium between the supply and demand side of the market held the cost of Ivermectin on the lower side. Furthermore, resumption in import and export activities kept the market sentiments at ease. Weak market sentiments from the pharmaceutical sector compelled domestic merchants to lower their quotations to encourage more end-user enquires. The values accessed at the end of Q3 were USD 32330/MT, with an average quarterly declination of 2.13%
Asia
In the third quarter of 2022, the Ivermectin market decreased significantly owing to ease in geopolitical conflicts and other logistics issues. Stable demand from the pharmaceutical sector with sufficient inventories kept the market sentiments at ease. With the improved pandemic situation in the APAC region influenced the ivermectin prices in the domestic market. Also, the release of lockdown imposition followed by production resumption in Shanghai resulted in a better supply chain scenario. Towards the end of Q3, the prices of Ivermectin were recorded at USD 29550/ton FOB Shanghai (China), with an average quarterly declination of 2.47%.
Europe
In the third quarter (Q3) of 2022, the prices of Ivermectin showcased a depreciating price trajectory as the downstream pharmaceutical sector's demand for Ivermectin was recorded to decline drastically. At the onset of the first half of Q3 2022, with sluggish demand from the pharmaceutical industry, the prices went down in the European market. Furthermore, with surplus inventories and firm supply, the ivermectin market showcased soft sentiments. With the ease in lockdown in exporting countries, and increased operating rates, Ivermectin's price continued to depreciate in the European market. Towards the end of Q3 2022, the prices of Ivermectin were recorded at USD 34250/ton with an average quarterly declination of 1.62%.
For the Quarter Ending June 2022
North America
The prices of Ivermectin showcased mixed behaviour in the North American region. At the onset of Q2 2022, the costs increased due to strict policies in exporting countries following the resumption of the pandemic, despite sluggish downstream demand from the pharmaceutical industry. Towards the commencement of the second half of Q2 2022, resumption in import and export activities kept the market sentiments at ease. Equilibrium between the supply and demand side of the market held the cost of Ivermectin on the stable side. Weak market sentiments from the pharmaceutical sector compelled domestic merchants to lower their quotations. The values accessed at the end of Q2 were USD 138670/MT with a quarterly declination of 0.69%
Asia
In the second quarter of 2022, the Ivermectin market increased significantly due to geopolitical conflicts and other logistics issues despite stable demand from the pharmaceutical sector. The rising incidence of COVID-19 with lockdown implications surged the market prices for Ivermectin. Also, the lockdown imposition followed by the pandemic resurgence in Shanghai disrupted the supply chain, leading ivermectin prices to inflate. Towards the end of Q2, the prices of Ivermectin were recorded at USD 129920/ton FOB Shanghai (China), with a quarterly inclination of 11.3%.
Europe
In the second quarter (Q2) of 2022, the prices of Ivermectin showcased a seesaw price trajectory as the downstream pharmaceutical sector's demand for Ivermectin was recorded to be stable. At the onset of the first half of Q2 2022, with sluggish demand from the pharmaceutical industry, the prices went down in the European market. Also, due to the surplus inventories and stable supply, the ivermectin market showcased feeble sentiments. At the beginning of the second half of Q2 2022, with lockdown imposition in exporting countries, and increased operating costs, Ivermectin's price increased in the European market. Towards the end of Q2 2022, the prices of Ivermectin were recorded at USD 153890/ton with a quarterly declination of 0.94%
